Precision NanoSystems Receives NRC-IRAP Funding to Support Development of the NanoAssemblr Nanoparticle Manufacturing Platform

Press Release

May 18, 2011

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, was awarded $47,000 by the National Research Council’s Industrial Research Assistance Program (NRC-IRAP) to support the development and optimization of scale-up processes for the manufacture of bioactive nanoparticles.

Precision NanoSystems CEO James Taylor, Ph.D. commented, “Precision would like to thank NRC-IRAP and particular our ITA, Graham North for their help, advice and ongoing support as we develop our prototype products towards commercialization. This award will support the development of a crucial aspect of our technology and is essential in order for us to maximize the value of this technology for Precision and Canada.”

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.

About NRC-IRAP 

The National Research Council – Industrial Research Assistance Program (NRC-IRAP) is Canada’s premier innovation assistance program for small and medium-sized enterprises (SMEs). It is a vital component of the NRC,a cornerstone in Canada’s innovation system, regarded world-wide as one of the best programs of its kind. For more information:http://www.nrc-cnrc.gc.ca/eng/ibp/irap.html


IN THE NEWS

Press Release

Vancouver, British Columbia Precision NanoSystems (PNI) is honored that our CEO & Co-Founder, James Taylor, was asked by the Consulate General of Canada to speak during the CEO Roundtable Panel at the upcoming Dose in the Valley Program Co...

Read More


News Article

The NIH and Moderna have begun phase 1 clinical trials for a vaccine to protect against COVID-19. The vaccine, called mRNA-1273, is an advanced mRNA vaccine that utilizes genetic material to immunize patients. Moderna and the NIH were able to bring mRNA-1273 to clinical trials wi...
Read More